BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of over 1000 found
  Current Search:  clinic: 26700, phase: 10671     

HTML
100%
OSI Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript
Gabe Leung - EVP and President of Oncology Anker Lundemose - President of our Diabetes/Obesity Business Analysts Joel Sendek - Lazard Capital Markets Maged Shenouda - UBS May-Kin Ho - Goldman Sachs Matt Roden - JPMorgan Mike King - Rodman ...
Yahoo!:  Jul 24 2008 2:08AM
Matching: clinic phase
Find similar documents
HTML
100%
CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day
- CombinatoRx, Incorporated (NASDAQ: CRXX) today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its corporate headquarters in Cambridge, MA...
Pharma Live:  Jul 24 2008 1:15AM
Matching: clinic phase
Find similar documents
HTML
100%
Duska Therapeutics Submits Phase 3 ATPace Protocol to FDA for Comment
/PRNewswire-FirstCall/ -- Duska Therapeutics, Inc.

('Duska') announced today that it has submitted for comment a synopsis of a proposed Phase 3 clinical study for its lead drug, ATPace(TM), to the U.S.

Food and Drug...

Pharma Live:  Jul 24 2008 1:16AM
Matching: clinic phase
Find similar documents
HTML
100%
Biodel Announces Publications Demonstrating Superior Metabolic Profile of VIAject Compared to the Rapid-acting
- Biodel Inc.

(Nasdaq: BIOD) announced today the publication of positive findings from studies demonstrating the superior metabolic profile of VIAject(TM) ultra rapid-acting insulin compared to the rapid-acting analog, Humalog(R), and...

Pharma Live:  Jul 24 2008 12:47PM
Matching: clinic phase
Find similar documents
HTML
100%
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Suppressed HIV-1 Viral Load and Increa
ISENTRESS(R) (raltegravir), Merck's first-in-class HIV-1 integrase inhibitor, suppressed HIV-1 viral load and increased CD4 cell counts through 48 weeks of combination therapy with other anti-HIV medicines compared to placebo in combination...
Genetic Engineering News:  Jul 24 2008 1:06AM
Matching: clinic phase
Find similar documents
HTML
100%
Sangamo BioSciences Reports Second Quarter 2008 Financial Results
RICHMOND, Calif., July 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.

today reported second quarter 2008 financial results and accomplishments.

For the second quarter ended June 30, 2008, Sangamo reported a consolidated net loss...

KRON4:  Jul 24 2008 9:53AM
Matching: clinic phase
Find similar documents
HTML
100%
Sangamo BioSciences Reports Second Quarter 2008 Financial Results
RICHMOND, Calif., July 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.

today reported second quarter 2008 financial results and accomplishments.

For the second quarter ended June 30, 2008, Sangamo reported a consolidated net loss...

KLFY:  Jul 24 2008 4:20AM
Matching: clinic phase
Find similar documents
HTML
100%
Elan Reports Second Quarter 2008 Financial Results
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc today announced its second quarter 2008 financial results and provided a business update.

Commenting on Elans business, Kelly Martin, Elans president and chief executive officer, said...

Business Wire via Yahoo!:  Jul 24 2008 6:12AM
Matching: clinic phase
Find similar documents
HTML
100%
Nuvelo Reports Second Quarter 2008 Financial Results
SAN CARLOS, Calif., July 23 /PRNewswire-FirstCall/ -- Nuvelo, Inc.

today announced second quarter 2008 financial results and accomplishments.

For the second quarter ended June 30, 2008, Nuvelo reported a net loss of $0.2 million or $0.00...

KRON4:  Jul 24 2008 9:52AM
Matching: clinic phase
Find similar documents
HTML
100%
Nuvelo Reports Second Quarter 2008 Financial Results
SAN CARLOS, Calif., July 23 /PRNewswire-FirstCall/ -- Nuvelo, Inc.

today announced second quarter 2008 financial results and accomplishments.

For the second quarter ended June 30, 2008, Nuvelo reported a net loss of $0.2 million or $0.00...

KLFY:  Jul 24 2008 4:19AM
Matching: clinic phase
Find similar documents
HTML
100%
Nuvelo Reports Second Quarter 2008 Financial Results
SAN CARLOS, Calif., July 23 /PRNewswire-FirstCall/ -- Nuvelo, Inc.

today announced second quarter 2008 financial results and accomplishments.

For the second quarter ended June 30, 2008, Nuvelo reported a net loss of $0.2 million or $0.00...

KOTA Territory News:  Jul 24 2008 3:49AM
Matching: clinic phase
Find similar documents
HTML
100%
Is it end of inhalable exubera
In October 2007, Pfizer, one of the largest global pharmaceutical companies, took the market by surprise by announcing its decision to discontinue the production of Exubera [rDNA origin], the inhalable powder formulation of insulin for the...
Bio Spectrum Asia:  Jul 24 2008 1:03PM
Matching: clinic phase
Find similar documents
HTML
100%
The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overal
- Nexavar is First Approved Systemic Therapy to Treat the Disease - WAYNE, N.J.

and EMERYVILLE, Calif., July 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.

today announced that The New...

KLFY:  Jul 24 2008 4:19AM
Matching: clinic phase
Find similar documents
HTML
100%
Genzyme Corp. Q2 2008 Earnings Call Transcript
Thanks, Mary Ann, and welcome everyone to Genzyme Corporation's second quarter Earnings Call.

On this call, we will be making forward-looking statements, including providing EPS guidance, discussing our product development plans and...

Yahoo!:  Jul 23 2008 10:35PM
Matching: clinic phase
Find similar documents
HTML
100%
FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Trace
BOSTON, July 23 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I results for BFPET, its novel Fluorine-18...
KOTA Territory News:  Jul 24 2008 3:50AM
Matching: clinic phase
Find similar documents
HTML
100%
Avigen's AV650 Patent Strategy Leads to Expanded Development Agreement
(PRIME NEWSWIRE) -- Avigen, Inc.

(Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today announced an amendment to the company's contract with Sanochemia Pharmazeutika AG, Avigen's development...

Pharma Live:  Jul 24 2008 1:16AM
Matching: clinic phase
Find similar documents
HTML
100%
Seattle Genetics Inc. Q2 2008 Earnings Call Transcript
Good afternoon ladies and gentlemen.

Thank you for standing by.

Welcome to the Seattle Genetics second quarter 2008 financial results conference call.

(Operator instructions) This conference is being recorded today, Tuesday July 22,...

Yahoo!:  Jul 23 2008 1:19AM
Matching: clinic phase
Find similar documents
HTML
100%
Dyax Corp. Q2 2008 Earnings Call Transcript
Dyax Corp.

(DYAX) Executives Henry Blair Chairman, President and CEO Gustav Christensen EVP and Chief Business Officer Bill Pullman EVP and Chief Development Officer Analysts Mark Monane Needham & Company Jason Kolbert SIG Phil...

Yahoo!:  Jul 23 2008 7:14PM
Matching: clinic phase
Find similar documents
HTML
100%
CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day
CombinatoRx, Incorporated (NASDAQ: CRXX) today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its corporate headquarters in Cambridge, MA....
Genetic Engineering News:  Jul 23 2008 2:27PM
Matching: clinic phase
Find similar documents
HTML
100%
CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day
CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX - News) today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its...
Yahoo!:  Jul 23 2008 1:31PM
Matching: clinic phase
Find similar documents
HTML
100%
Forest Laboratories Inc. F4Q09 (Qtr End 6/30/08) Earnings Call Transcript
Frank Perier, Jr - SVP, Finance and CFO Larry Olanoff - President and COO Analysts Rich Silver - Lehman Brothers Greg Gilbert - Merrill Lynch Frank Pinkerton - Banc of America Securities Corey Davis - Natixis Bleichroeder Annabel Samimy --...
Seeking Alpha:  Jul 23 2008 12:37PM
Matching: clinic phase
Find similar documents
HTML
100%
Biogen IDEC, Inc. Q2 2008 Earnings Call Transcript
James C.

Mullen - President and CEO Bill Sibold - Sr.

VP, US Commercial Al Sandrock - Sr.

VP, Neurology Research and Development Paul J.

Clancy - EVP and CFO Analysts Michael Aberman - Credit Suisse Geoffrey Meacham - JPMorgan Yaron...

Yahoo!:  Jul 23 2008 3:06AM
Matching: clinic phase
Find similar documents
HTML
100%
From Whole-Gland to Targeted Cryoablation for the Treatment of Unilateral or Focal Prostate Can
Division of Urologic Surgery and Duke Prostate Center (DPC) Department of Surgery Duke University Medical Center Durham, North Carolina The intermediate and long-term results of primary full-gland cryoablation for localized prostate cancer...
Consultant Live:  Jul 23 2008 8:04PM
Matching: clinic phase
Find similar documents
HTML
100%
Methylgene and Celgene announce precautionary suspension of new enrollments into MGCD0103 clinical trials
Montreal, Quebec and Summit, NJ - MethylGene Inc.

(TSX:MYG) and Celgene Corporation today announced that, at the recommendation of a standing internal safety committee, the companies are temporarily suspending enrollment of new patients...

Checkbiotech:  Jul 23 2008 12:59PM
Matching: clinic phase
Find similar documents
HTML
100%
CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima Using I
- State-of-the-Art PET Study Confirms Tyrima Exhibits Excellent Drug-Like Properties - RESEARCH TRIANGLE PARK, N.C., July 22, 2008 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing...
Pharmalive.com:  Jul 23 2008 1:13AM
Matching: clinic phase
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.